Home Clinical Trials PCYC-1106-CA: BTK Inhibitor - Relapsed or Refractory Non-Hodgkin’s DLBCL Lymphoma
Print

PCYC-1106-CA: Safety and Efficacy of BTK Inhibitor in Subjects with Relapsed or Refractory Non-Hodgkin's Diffuse Large B-cell Lymphoma

PCYC-1106-CA: Safety and Efficacy of BTK Inhibitor in Subjects with Relapsed or Refractory Non-Hodgkin’s Diffuse Large B-cell Lymphoma

      To access the most up-to-date information on this study,
      please refer to this page at ClinicalTrials.gov.

Official Title

A Multicenter, Open-label, Phase II, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765, in Subjects with Relapsed or Refractory or de Novo Diffuse Large B-cell Lymphoma (DLBCL)

Purpose

The purpose of this study is to establish the safety and efficacy of PCI-32765 in patients with Non-Hodgkin diffuse large B-cell lymphoma (DLBCL).